How long does it take for Dacomitinib to become resistant?

Dacomitinib (Dacomitinib) is a second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used to treat non-small cell lung cancer (NSCLC). Although dacomitinib (dacomitinib) has shown efficacy in the treatment of EGFR mutant NSCLC, the problem of drug resistance is still inevitable. Generally, patients will gradually develop drug resistance after taking dacomitinib for a period of time, leading to disease progression.

Clinical data show thatdacomitinib has a median progression-free survival (PFS) of 14.7 months. This means that during this period, most patients' disease will not worsen. However, this is only a median, and the specific resistance time varies among individuals. Some patients may develop resistance within a shorter period of time, while others may remain effective for a longer period of time.

The most common resistance mechanism is new mutations in the EGFR gene, such as the T790M mutation. This mutation alters the structure of the tyrosine kinase, making it less sensitive to dacomitinib (dacomitinib). Cancer cells may escape the inhibitory effects of Dacomitinib by activating other signaling pathways, such as MET amplification, HER2 HER2 amplification, or the RAS-RAF-MEK pathway. Cancer cells may undergo a phenotypic switch, such as from adenocarcinoma to small cell lung cancer or epithelial-to-mesenchymal transition (EMT), thereby escaping the effects of dacomitinib. The body's metabolism and excretion mechanism of drugs may also change, affectingthe drug concentration and efficacy of dacomitinib (dacomitinib).

Once resistance occurs, doctors usually adjust treatment strategies based on the specific resistance mechanism. For example, for patients with the T790M mutation, third-generation EGFR-TKIs such as Osimertinib (Osimertinib) for treatment. For other resistance mechanisms, combination therapy or the use of other types of targeted drugs may be needed.

In order to delay the development of drug resistance, researchers are also exploring various combination treatment options, including the combination of EGFR-TKI with anti-angiogenic drugs, immunotherapy drugs or other targeted drugs. In addition, regular monitoring of patients' disease progression and gene mutation status is of great significance for timely adjustment of treatment plans and prolonging patients' progression-free survival.